Vigabatrin Powder, For Solution
Product Images NDC 59651-366

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Vigabatrin (NDC 59651-366). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Vigabatrin Fig1)

This appears to be a graph displaying the percentage reduction in seizure frequency for different treatment groups. The treatments are referred to as Plcsbo, Tolday, aglday V68, and bgiday. The x-axis displays the percentage of patients in the treatment group and the y-axis shows the percent reduction in seizure frequency. The graph shows three groups with varying degrees of improvement, no change or worsening. No further context is available to interpret the origin, purpose, or nature of the data.*

FDA Label Image

Figure F (Vigabatrin Fig10)

FDA Label Image

Figure G (Vigabatrin Fig11)

FDA Label Image

Figure H (Vigabatrin Fig12)

FDA Label Image

Figure I (Vigabatrin Fig13)

FDA Label Image

Figure J (Vigabatrin Fig14)

FDA Label Image

Package Label-principal Display Panel (500 mg (Packet))

FDA Label Image

Package Label-principal Display Panel (500 mg (50 Packets Carton))

This text is the description of Vigabatrin for Oral Solution. It includes directions for use, storage information, and a recommendation for dispensing the medication guide to each patient. The package contains 50 packets which are to be separately mixed with 0 mL of water and immediately administered. The package is not child-resistant and should be stored at controlled room temperature. The medication is manufactured by Aurobindo Pharma USA, Inc. and the provided code is APDRUGSI2016.*

FDA Label Image

Figure 2 (Vigabatrin Fig2)

The text describes a figure labeled as Figure 2 that displays the percentage reduction in seizures in patients from baseline. The figure includes a chart with the percentage on the y-axis and the percentage of patients on the x-axis. The chart shows that some patients had a reduction of 100% while others showed no change or worsening. The caption indicates that a placebo was involved in the study.*

FDA Label Image

Figure3 (Vigabatrin Fig3)

FDA Label Image

Oral Syringe Detail (Vigabatrin Fig4)

This text seems to be a short phrase that doesn't provide enough context for generating a useful description. It is possible that this text describes an image or a document that has more information on "Oral syringe detail". Without any additional context, it is not possible to generate a meaningful description.*

FDA Label Image

Figure5 (Vigabatrin Fig5)

FDA Label Image

Figure B (Vigabatrin Fig6)

FDA Label Image

Figure C (Vigabatrin Fig7)

FDA Label Image

Figure D (Vigabatrin Fig8)

FDA Label Image

Figure E (Vigabatrin Fig9)

FDA Label Image

Chemical Structure (Vigabatrin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.